Compared with traditional benzodiazepines and non-benzodiazepine drugs, DORAs inhibit the hyperactive arousal pathway in patients with insomnia by blocking orexin function (Beuckmann et al., 2017; Xue et al., 2023). The gene discussed is HCRT; the disease is insomnia.